Cabazitaxel
- Generic Name
- Cabazitaxel
- Brand Names
- Jevtana, Cabazitaxel Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C45H57NO14
- CAS Number
- 183133-96-2
- Unique Ingredient Identifier
- 51F690397J
- Background
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like paclitaxel and docetaxel.
Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
- Indication
用于治疗转移性去势抵抗性前列腺癌患者。
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT01497964
- Locations
- 🇰🇷
Investigational Site Number 410001, Seoul, Korea, Republic of
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
- Conditions
- Recurrent Prostate CancerStage I Prostate CancerDiarrheaStage IIB Prostate CancerHormone-resistant Prostate CancerStage IIA Prostate CancerStage III Prostate CancerStage IV Prostate Cancer
- Interventions
- Other: questionnaire administration
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 9
- Registration Number
- NCT01469338
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT01447225
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2025-05-04
- Target Recruit Count
- 14
- Registration Number
- NCT01437488
- Locations
- 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Radiation: Intensity Modulated Radiation Therapy (IMRT)Genetic: Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- First Posted Date
- 2011-08-19
- Last Posted Date
- 2025-05-15
- Target Recruit Count
- 20
- Registration Number
- NCT01420250
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Cabazitaxel - PF Induction Chemotherapy
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2011-06-23
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- Krzysztof Misiukiewicz
- Target Recruit Count
- 40
- Registration Number
- NCT01379339
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
- Conditions
- Gastric CancerGastrooesophageal CancerEsophageal
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- howard safran
- Target Recruit Count
- 15
- Registration Number
- NCT01365130
- Locations
- 🇺🇸
Memorial Hospital, Pawtucket, Rhode Island, United States
🇺🇸Brown University Oncology Research Group, Providence, Rhode Island, United States
🇺🇸Roger Williams, Providence, Rhode Island, United States
Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
- Conditions
- Prostatic NeoplasmsProstate Cancer
- Interventions
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 4
- Registration Number
- NCT01335204
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT01324583
- Locations
- 🇯🇵
Investigational Site Number 392008, Maebashi-Shi, Japan
🇯🇵Investigational Site Number 392015, Nagoya-Shi, Japan
🇯🇵Investigational Site Number 392003, Sunto-Gun, Japan
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1200
- Registration Number
- NCT01308580
- Locations
- 🇺🇸
Investigational Site Number 840014, Baltimore, Maryland, United States
🇺🇸Investigational Site Number 840021, Stamford, Connecticut, United States
🇺🇸Investigational Site Number 840020, Akron, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.